Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participants with type 1 diabetes~* Body mass index (BMI) between 18.5 and 30.0 kilograms per square meter, inclusive~* Hemoglobin A1c (HbA1c) less than or equal to 8.5 percent (%)~* Using CSII and stable insulin regimen for at least 3 months prior to inclusion into the trial~Exclusion Criteria:~* Known or suspected hypersensitivity to investigational medical product(s) or related products~* Receipt of any medicinal product in clinical development within 30 days or at least 5 half-lives of the related substances and their metabolites (whichever is longer) before randomization in this trial~* Known slowing of gastric emptying and or gastrointestinal surgery that, in the opinion of the investigator, might change gastrointestinal motility and food absorption~* Proliferative retinopathy or maculopathy as judged by the Investigator based on a recent (less than 1.5 years) ophthalmologic examination~* Widespread subcutaneous lipodystrophy in the abdomen~* Current use of any glucose-lowering agents other than insulin within 3 months prior to screening~* Chronic or recent use of corticosteroids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- 100 U/mL LY900014 (Type: EXPERIMENTAL): 100 units per milliliter (U/mL) LY900014 administered by continuous subcutaneous insulin infusion (CSII) in one of two study periods.
- 100 U/mL Insulin Lispro (Humalog) (Type: ACTIVE_COMPARATOR): 100 U/mL Insulin Lispro (Humalog) administered by CSII in one of two study periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).